THERAtRAME SA
10.1 FTEThe score of THERAtRAME shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2023 → 2025: Equity -5 % Total assets +8 % Headcount (avg FTE) +288 %
Accounts of the company itself (not consolidated).
The full file covers 3 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
THERAtRAME's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 09 Jul 2026
- Year ended 31 Dec 2024filed on 21 Aug 2025
- Year ended 31 Dec 2023filed on 26 Jun 2024
THERAtRAME's financial analysis
- Solvency65.8%sector median: 57.9%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of THERAtRAME
THERAtRAME's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0786.448.581
- VAT number
- BE0786448581
- Peppol
- Registered · 0208:0786448581 · as of 10 Nov 2026
- Legal form
- SA
- Incorporated
- 23 May 2022
- Registered office
- 4000 Liège
- Size
- Small · 10.1 FTE
- Latest accounts
- 2025 · filed on 09 Jul 2026
- Activity
- Research and experimental development on biotechnology (NACE 72101)
THERAtRAME (SA) has been based in Liège since 2022, active in: research and experimental development on biotechnology. For 2025, it reports a net loss of €2.12m and equity of €1.75m; its revenue is not published. With 10.1 full-time equivalents, it is a small enterprise by headcount. Its solvency stands at 65.8%, above the median of its sector (57.9%).
Companies similar to THERAtRAME
Companies in the same business, of comparable size and area, outside its group.
- Puxano Research and experimental development on natural sciences and engineering Ghent · balance sheet €2.43m
- Stam Agro Research and experimental development on natural sciences and engineering Dendermonde · balance sheet €1.86m
- ConvEyXo Research and experimental development on natural sciences and engineering Charleroi · balance sheet €10.3m
- Inhatarget Therapeutics Research and experimental development on natural sciences and engineering Charleroi · balance sheet €2.16m
- Dendrogenix Research and experimental development on natural sciences and engineering Liège · balance sheet €5.28m
- Abaxys Therapeutics Research and experimental development on natural sciences and engineering Villers-la-Ville · balance sheet €1.31m
- Novobiom Research and experimental development on natural sciences and engineering Liège · balance sheet €3.92m
- Railroad Therapeutics Research and experimental development on natural sciences and engineering Charleroi · balance sheet 619,622 €
Frequently asked questions about THERAtRAME
What is the revenue of THERAtRAME?
THERAtRAME files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of THERAtRAME?
In Belgium, the VAT number is the company number prefixed with BE: BE0786448581 for THERAtRAME, if the company is VAT-registered. Its company number (CBE) is 0786.448.581.
Where is the registered office of THERAtRAME?
According to the CBE register, the registered office of THERAtRAME is in 4000 Liège.
What is the equity of THERAtRAME?
At the close of the 2025 financial year, the equity of THERAtRAME amounts to 1,753,432 €, a solvency of 65.8% of total assets.
How many people work at THERAtRAME?
10.1 full-time equivalents on average according to the 2025 social balance sheet.
Who manages THERAtRAME?
The register lists 14 active mandates at THERAtRAME. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of THERAtRAME
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →